Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BJTJ-0063
- Development stage
- Preclinical
- Lead developer
- Beijing Tuojie Biomedical Technology
01
Overview
BJTJ-0063 is a preclinical-stage drug candidate being developed by Beijing Tuobixi Pharmaceutical (also known as Beijing Tuojie Pharmaceutical). The drug is intended for the treatment of metabolic disorders, specifically diabetes and obesity. As of the current pipeline information, BJTJ-0063 is in the early stages of research and development. While specific details regarding its molecular target, mechanism of action, or chemical modality have not been publicly disclosed, it is part of the company's expanding portfolio of metabolic and cardiovascular treatments, which often involves collaborations with partners such as Meiji Seika Pharma.
Beyond the preview
Go deeper on BJTJ-0063.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BJTJ-0063.